EUVIMEDEUVIMED entdecken
Open Access

Cucurbitacin IIa promotes the immunogenic cell death‑inducing effect of doxorubicin and modulates immune microenvironment in liver cancer

Sujuan Li, Sen Wang, Anping Zhang, Lixia Luo, Jie Song, Guoli Wei, Zhijun Fang

International Journal of Oncology · 2024

DOI: 10.3892/ijo.2024.5625 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Oncology, 2024. Verfasst von Sujuan Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R. Chi…. Hauptthemen laut MEDLINE: Immunogenic Cell Death, Liver Neoplasms, Cucurbitacins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The immunogenic cell death (ICD) has aroused great interest in cancer immunotherapy. Doxorubicin (DOX), which can induce ICD, is a widely used chemotherapeutic drug in liver cancer. However, DOX‑induced ICD is not potent enough to initiate a satisfactory immune response. Cucurbitacin IIa (CUIIa), a tetracyclic triterpene, is a biologically active compound present in the Cucurbitaceae family. The present study assessed the effects of the combination of DOX and CUIIa on the viability, colony formation, apoptosis and cell cycle of HepG2 cells. In vivo anticancer effect was performed in mice bearing H22 tumor xenografts. The hallmark expression of ICD was tested using immunofluorescence and an ATP assay kit. The immune microenvironment was analyzed using flow cytometry. The combination of CUIIa and DOX displayed potent apoptosis inducing, cell cycle arresting and in vivo anticancer effects, along with attenuated cardiotoxicity in H22 mice. The combination of DOX and CUIIa also facilitated ICD as manifested by elevated high‑mobility group box 1, calreticulin and ATP secretion. This combination provoked a stronger immune response in H22 mice, including dendritic cell activation, increment of cytotoxic T cells and T helper 1 cells. Moreover, the proportion of immunosuppressive cells including myeloid‑derived suppressor cells, T regulatory cells and M2‑polarized macrophages, decreased. These data suggested that CUIIa is a promising combination partner with DOX for liver cancer treatment, probably via triggering ICD and remolding the immune microenvironment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunogenic Cell DeathLiver NeoplasmsCucurbitacinsHumansAnimalsMiceDoxorubicinAdenosine TriphosphateCell Line, TumorImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

CUIIaDOXICDTMEliver cancer

Substanzen

cucurbitacin IIaDoxorubicinAdenosine TriphosphateCucurbitacins

Autor:innen und Institutionen

  • Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R. China.

Zitieren

APA

Li, S., Wang, S., Zhang, A., Luo, L., Song, J., Wei, G., & Fang, Z. (2024). Cucurbitacin IIa promotes the immunogenic cell death‑inducing effect of doxorubicin and modulates immune microenvironment in liver cancer. International Journal of Oncology. https://doi.org/10.3892/ijo.2024.5625

Vancouver

Li S, Wang S, Zhang A, Luo L, Song J, Wei G, et al. Cucurbitacin IIa promotes the immunogenic cell death‑inducing effect of doxorubicin and modulates immune microenvironment in liver cancer. International Journal of Oncology. 2024. doi:10.3892/ijo.2024.5625

BibTeX
@article{Li2024,
  author = {Li, Sujuan and Wang, Sen and Zhang, Anping and Luo, Lixia and Song, Jie and Wei, Guoli and Fang, Zhijun},
  title = {Cucurbitacin IIa promotes the immunogenic cell death‑inducing effect of doxorubicin and modulates immune microenvironment in liver cancer},
  journal = {International Journal of Oncology},
  year = {2024},
  doi = {10.3892/ijo.2024.5625}
}
Kostenlos starten →